Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Christina Soubrane"'
Autor:
Yannick Allanore, Sylvie Bozzi, Augustin Terlinden, Doerte Huscher, Caroline Amand, Christina Soubrane, Elise Siegert, László Czirják, Patricia E. Carreira, Eric Hachulla, Elisabetta Zanatta, Mengtao Li, Paolo Airò, Fabian A. Mendoza, Edoardo Rosato, Oliver Distler, on behalf of the EUSTAR Collaborators
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020)
Abstract Background Patients with diffuse cutaneous systemic sclerosis (dcSSc) have a poor prognosis. The importance of monitoring subjective measures of functioning and disability, such as the Health Assessment Questionnaire-Disability Index (HAQ-DI
Externí odkaz:
https://doaj.org/article/b0740c2493be40d498a6dc3efcc2210a
Autor:
Peter Wung, Yannick Allanore, Frederic Marrache, Corinne Esperet, Amel Lahmar, Dinesh Khanna, Investigators, Christopher P. Denton, Christina Soubrane, Raphael Bejuit
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesRecent advances in systemic sclerosis (SSc) show that it involves a T-helper type-2-oriented immune response with interleukin (IL)-4 and IL-13. Romilkimab is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neu
Autor:
Marie-Laure Ozoux, Valerie Martin, Arun Subramaniam, Alexandre Jagerschmidt, Luca Richeldi, Christina Soubrane, Ganesh Raghu, Corinne Esperet
Publikováno v:
Chest. 154:1359-1370
Background Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with 3 to 5 years' survival. Although FVC is used to assess disease progression and treatment response, identifying predictive circulating blood biomarkers could help identify spe
Autor:
Christopher P. Denton, Dinesh Khanna, Raphael Bejuit, Peter Wung, M. Frederic, Christina Soubrane, A. Lahmar, Corinne Esperet, Y. Allanore
Publikováno v:
Annals of the Rheumatic Diseases. 79:157-158
Background:Systemic sclerosis (SSc) is a progressive, multi-organ disease with limited treatment options. Interleukin-4 (IL-4) and IL-13 have been implicated in the fibrotic pathway and pathogenesis of SSc and are promising targets. Romilkimab (RKB)
Publikováno v:
Idiopathic interstitial pneumonias.
Rationale: Prevalence of ANA is not very well characterized in idiopathic pulmonary fibrosis (IPF). While ANA is used in the evaluation of patients with suspected IPF to exclude mimickers of fibrotic lung disease, its clinical significance in patient
Autor:
Christian Antoni, Corinne Esperet, Raphael Bejuit, Ganesh Raghu, Peter Wung, Bruno Crestani, Luca Richeldi, Christina Soubrane
Publikováno v:
The European respiratory journal. 52(6)
A phase 2b trial (NCT02345070) was conducted to evaluate the efficacy and safety of two dose levels/regimens of SAR156597 (a bispecific IgG4 antibody that binds and neutralises both circulating interleukin-4 and interleukin-13), in comparison with pl
Autor:
Ganesh, Raghu, Luca, Richeldi, Alexandre, Jagerschmidt, Valerie, Martin, Arun, Subramaniam, Marie-Laure, Ozoux, Corinne A, Esperet, Christina, Soubrane
Publikováno v:
Chest. 154(6)
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with 3 to 5 years' survival. Although FVC is used to assess disease progression and treatment response, identifying predictive circulating blood biomarkers could help identify specific biolo
Publikováno v:
The American Journal of Geriatric Psychiatry. 16:44-57
Objectives To evaluate the clinical efficacy and safety of zolpidem extended release for the treatment of primary insomnia in elderly patients. Methods A randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A tot
Publikováno v:
Sleep Medicine. 7:397-406
Background and purpose To evaluate the clinical efficacy and safety of modified-release zolpidem (zolpidem-MR 12.5 mg) for the treatment of primary insomnia in adults. Patients and methods Two hundred and twelve (123 women, 89 men; mean age 44.3±SD
Publikováno v:
Sleep. 31(1)
To evaluate long-term efficacy and safety of zolpidem extended-release 3 to 7 nights/week for chronic primary insomnia.Multicenter, 25-week, phase IIIb, randomized, double-blind, placebo-controlled, parallel-group.Outpatient; visits every 4 weeks.Age